Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 0.00000
forwardPE 24.69675
debtToEquity 1.34300
earningsGrowth 0.04600
revenueGrowth 0.13800
grossMargins 0.76052
operatingMargins 0.25733
trailingEps 74.39000
forwardEps 99.28000

Ajanta Pharma Limited's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
Positive gross and operating margins for Ajanta Pharma Limited highlight the company's profitability. These metrics reflect Ajanta Pharma Limited's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
AJANTPHARM's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting AJANTPHARM to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


There were 11 AJANTPHARM stock sales, with market price at 2984.895441228693.Throughout the period under consideration, there were no sell transactions.AJANTPHARM's current price levels are seeing more buying activity than selling, which might indicate a bullish sentiment. Investors appear to be confident, interpreting the buying trend as a sign of positive expectations for the stock's future performance.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts' buy bias for AJANTPHARM signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to AJANTPHARM, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.